

07 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/07/3214944/0/en/Onco360-Has-Partnered-with-Rigel-Pharmaceuticals-to-Add-Three-Therapies-to-Its-Limited-Distribution-Portfolio.html

17 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigel-announces-publication-of-final-5-year-data-on-rezlidhia-olutasidenib-in-patients-with-rr-midh1-aml-in-the-journal-of-hematology--oncology-302616427.html

03 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigel-announces-one-oral-and-four-poster-presentations-at-the-67th-american-society-of-hematology-annual-meeting-and-exposition-302602603.html

05 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigel-announces-first-patient-enrolled-in-phase-1b2-triplet-therapy-trial-of-rezlidhia-olutasidenib-in-midh1-aml-302238788.html

06 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html

04 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rigel-announces-publication-of-data-on-rezlidhia-olutasidenib-in-post-venetoclax-patients-with-mutant-idh1-aml-in-leukemia--lymphoma-302107833.html